SEC Form 4Coverage since May 29, 2026
$PTGX insider trading
Over the last 12 months, Protagonist Therapeutics insiders reported no purchases and 3 sales totaling $2.9M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.9M 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $PTGX · 12Mvia TradingView
Top insiders · 12m
Waddill William D.—3× · $2.9M
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | Waddill William D.D | ▼ Sale | 9,000 | $117.94 | $1.1M | -53.5% | plan |
| Jun 10, 2026 | Waddill William D.D | ▼ Sale | 9,000 | $107.68 | $969K | -53.5% | plan |
| May 29, 2026 | Waddill William D.D | ▼ Sale | 9,000 | $99.64 | $897K | -53.5% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PTGX feed.